Medigene AG
XETRA MDG1.DE
Medigene AG Debt to Equity Ratio for the year ending December 31, 2023: 0.14
-
Medigene AG Debt to Equity Ratio for the year ending December 31, 2022 was 0.10, a 12.07% change year over year.
-
Medigene AG Debt to Equity Ratio for the year ending December 31, 2021 was 0.09, a -7.40% change year over year.
-
Medigene AG Debt to Equity Ratio for the year ending December 31, 2020 was 0.10, a 57.14% change year over year.
-
Medigene AG Debt to Equity Ratio for the year ending December 31, 2019 was 0.06, a 338.41% change year over year.
| Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
|---|
Don’t Miss A Beat
| CEO | Dr. Selwyn Ho MB BS, MBBS |
| IPO Date | June 30, 2000 |
| Location | Germany |
| Headquarters | Lochhamer Strasse 11 |
| Employees | 87 |
| Sector | Healthcare |
| Industries | |
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Past 5 years
USD 9.34
StockViz Staff
February 6, 2025
Any question? Send us an email